Volume 133, Issue 24



June 13, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Chronic CD30 signaling in B cells predisposes mice to lymphoma. See the article by Sperling et al.

The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing
In a Plenary Paper, Ishihara et al elucidate a critical novel role for von Willebrand factor outside coagulation. They demonstrate that the heparin-binding domain binds vascular endothelial growth factor and fibroblast growth factor, leading to angiogenesis and improved wound healing.

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
Winkler and colleagues report on the response of patients with refractory aplastic anemia treated with eltrombopag out to 24 weeks, demonstrating that prolonged treatment increases response. However, there is a rate of clonal evolution of nearly 20%, which manifests as cytogenetic abnormalities rather than expansion of somatically mutated clones.

Acalabrutinib for mantle cell lymphoma
In a Blood Spotlight, Witzig and Inwards highlight acalabrutinib, a novel second-generation oral Bruton tyrosine kinase inhibitor recently approved by the US Food and Drug Administration for the treatment of relapsed mantle cell lymphoma.

Engineered Bcor mutations lead to acute lymphoblastic leukemia of progenitor B-1 lymphocyte origin in a sensitized background
Yin et al introduced a Bcor mutation into hematopoietic stem cells of sensitized mice. Recipient mice acquired spontaneous JAK mutations and developed acute lymphoblastic leukemia (ALL) of B-1 lymphocyte origin, a model for human B-cell precursor ALL.

Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells
CD30 is expressed on a range of B-cell lymphomas, but its role in lymphomagenesis is unknown. Sperling et al examined mice expressing a constitutively active CD30 in B cells. They demonstrate that chronic CD30 overexpression leads to an increase in B-1 lymphocytes and plasma cells and that the mice develop lymphoma with aging.

With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study
It has been suggested that African Americans with multiple myeloma have outcomes inferior to those of white patients. Fillmore et al examined this using data from the US Department of Veterans Affairs registry and found that, given access to appropriate care, African Americans actually have superior outcomes with myeloma treatment.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.